Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiotherapy in NSCLC
NCT04398199Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Wake Forest University Health Sciences. Primary endpoint: Presence or Absence of In-Field Progression at 2 years. Started Oct 2020; status: terminated.
Beyond the preview
Go deeper on NCT04398199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398199.